ESMO Preceptorship on Non-Small Cell Lung Cancer Frankfurt, Germany, 14-15 October 2014 Standards of care, evolving paradigm and future perspective Co-Chairs Jean-Yves Douillard, France Enriqueta Felip, Spain Faculty Federico Cappuzzo, Italy Wilfried Eberhardt, Germany Dominique Grunenwald, France Keith Kerr, United Kingdom Luiz Paz-Ares, Spain Cecile Le Pechoux, France Solange Peters, Switzerland Egbert Smit, The Netherlands Rolf A. Stahel, Switzerland Learning Objectives: • To learn about best clinical practice in the management of Non-Small Cell Lung Cancer (NSCLC) in the adjuvant, locally advanced and metastatic settings • To understand the importance of pathology and histoprognostic factors in the management of NSCLC • To learn about the management of patients after progression, side‐effects of treatments, and the use of targeted agents in NSCLC Preliminary Programme Tuesday, 14 October 2014 14:00-14:15 15‘ 15‘ Opening and Welcome Chair: Enriqueta Felip, ES Welcome from ESMO, objectives and scientific introduction Jean‐Yves Douillard, FR 14:15-16:15 120‘ 30‘ 15‘ Session 1 Chair: Wilfried Eberhardt, DE Histopathology of NSCLC, IHC markers and pTNM classification State‐of‐the‐art: Standard of care for resectable NSCLC - Surgical approach for resectable NSCLC State‐of‐the‐art: Standard of care for resectable NSCLC - Adjuvant chemotherapy State-the-art for Locally Advanced unresectable/inoperable disease NSCLC: - Update on RT/CT for unresectable NSCLC - Stereotactic RT and IMRT for inoperable NSCLC Is there a place for neoadjuvant treatment? Keith Kerr, UK Dominique Grunenwald, FR 15’ 30‘ 30‘ 16:15-16:45 Break Jean Yves Douillard, FR Cecile Le Pechoux, FR Enriqueta Felip, ES Tuesday, 14 October 2014, cont. 16:45-17:45 60‘ 60‘ 19:30-22:30 Session 2 – case discussion Chair: Enriqueta Felip, ES Cases presented by participants and discussion by the Faculty Faculty Dinner Wednesday 15 October 2014 09:00-10:30 90‘ 45‘ 45‘ Session 3 - Metastatic NSCLC Chair: Solange Peters, CH 1st line chemotherapy and contribution of bevacizumab and impact of second-line chemotherapy in unselected patients Maintenance treatment - Chemo maintenance or targeted agents or both? Wilfried Eberhardt , DE Luis Paz-Ares, ES 10:30-11:00 Break 11:00-12:15 75‘ 45‘ Session 4 - Biomarker driven treatment Chair: Jean‐Yves Douillard, FR Biomarker driven treatment of selected NSCLC: EGFR - EGFR TKI in mutant EGFR NSCLC - Mechanisms of resistance and drugs in development Biomarkers driven treatment of selected NSCLC: ALK EML4 - Crizotinib - Crizotinib resistance - 2nd generation drugs Federico Cappuzzo , IT 30‘ 12:15-13:15 13:15-14:15 60‘ 30‘ Solange Peters, CH Lunch Session 5 Chair: Luis Paz-Ares, ES Strategic approaches: - Sequence of use of targeted agents and chemotherapy and definition of progression under TKI - Intercalating anti-EGFR with chemotherapy Management of targeted agents side-effects - The flare effect - Management of side-effects Egbert Smit, NL 14:15-15:15 60‘ 60‘ Session 6 - case discussion Chair: Egbert Smit, NL 3 x Cases presented by participants and discussion by the Faculty Faculty 15:15-15:45 30‘ 30‘ Session 7 – Words from the ESMO President Chair: Jean-Yves Douillard, CH - Promising innovating approached in NSCLC - ESMO oncopolicy in thoracic oncology Rolf A. Stahel, CH 15:45-16:00 15‘ Conclusion and take home messages Enriqueta Felip, ES 30‘ ESMO will apply for CME accreditation for this programme Solange Peters, CH